Odyralduo (Dorzolamide, Timolol)

Odyralduo combines dorzolamide and timolol to lower intra‑ocular pressure in conditions affecting aqueous humor dynamics.

• Open‑angle glaucoma: reduces intra‑ocular pressure, helping to prevent optic nerve damage.
• Ocular hypertension: lowers elevated eye pressure, decreasing risk of progression to glaucoma.
• Glaucoma (any type): provides pressure reduction across various glaucoma subtypes.

• Dorzolamide inhibits carbonic anhydrase II in the ciliary epithelium, decreasing bicarbonate formation and consequently reducing aqueous humor production. Timolol blocks β‑adrenergic receptors in the ciliary body, diminishing cyclic AMP‑mediated secretion of aqueous humor. By targeting two distinct pathways that regulate aqueous humor dynamics, the formulation achieves a more pronounced and sustained pressure‑lowering effect compared with either component alone.

Common ocular and systemic reactions have been reported with the use of dorzolamide/timolol eye drops.

Common Side Effects

• Eye irritation: transient burning or stinging upon instillation.
• Blurred vision: temporary reduction in visual clarity after dosing.
• Taste disturbance: bitter taste sensation in the throat.
• Dry eye: mild reduction in tear production.

Serious or Rare Side Effects

• Severe allergic reaction: swelling, rash, or difficulty breathing.
• Significant decrease in heart rate: bradycardia requiring medical attention.
• Exacerbation of asthma: bronchospasm in susceptible individuals.
• Persistent ocular pain: may indicate corneal involvement.

When prescribing or dispensing Odyralduo, several precautions should be observed to ensure safe use.

• Contraindication: do not use in patients with known hypersensitivity to dorzolamide, timolol or any component.
• Respiratory conditions: avoid in patients with severe asthma or chronic obstructive pulmonary disease.
• Cardiac disease: use cautiously in individuals with bradycardia, heart block, or heart failure.
• Pregnancy and lactation: safety not established; assess risk‑benefit before use.
• Contact lens wear: remove lenses before instillation and wait before reinserting.
• Store at room temperature: keep below 25°C in the original container, protected from light and moisture.

Odyralduo may interact with other medications affecting ocular pressure or systemic beta‑blockade.

Major Interactions (Avoid)

• Non‑selective beta‑blockers (e.g., propranolol): additive systemic beta‑blockade may cause bradycardia or hypotension.
• Systemic carbonic anhydrase inhibitors: increased risk of metabolic acidosis.
• MAO inhibitors: may potentiate ocular hypotensive effect leading to excessive pressure drop.

Moderate Interactions (Monitor Closely)

• Anticholinergic eye drops: may reduce efficacy of timolol.
• Diuretics (e.g., thiazides): may enhance dorzolamide‑induced electrolyte changes.
• Calcium channel blockers: possible additive cardiovascular effects.